Anavex Life Sciences Corp (AVXL)

[XenaLives]

Compiled Due Diligence 11/4/18

This is a wonderful board for collective effort, thanks to all who contribute. I have tried to organize this post as well as I could, suggestions and corrections are welcome. I'm sure I've missed some excellent recent posts because I was working on this. Please let me know.
_________________________________________________________________________________________________________________________
UPCOMING PRESENTATIONS AND OTHER POSSIBLE EVENTS:

On Nov 10th, 16th Asian Oceanian Congress of Neurology (AOCN) - Coex, Seoul Korea -

2:00-2:30 Oral presentation: Precision Medicine for Neurodegenerative Diseases- Harald Hampel
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144640427

Dec. 11 NYAS symposium, Alzheimer’s Disease Therapeutics: Alternatives to Amyloid, that Nell Rebowe is organizing with Dr. Rudy Tanzi and Dr. Howard Fillit of the Alzheimers's Drug Discovery Foundation.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979620
Pertinent comments on the above from TTAV: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144635533


February 19-21, 2019, Anavex will be participating in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/?tab=agenda

From the event’s description:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144414392

_________________________________________________________________________________________________________________________
Hampel Speaks!:

Harald Hampel may be the world's foremost authority on Alzheimer's. It is an honor to have him speak on behalf of Anavex.
https://www.alzforum.org/member-directory/harald-hampel-0

Hampel SPEAKS!....

AAIC August 2018
htps://investorshub.advfn.com/boards/read_msg.aspx?message_id=142864055
(video and ad hoc transcript above)
Slides:
https://www.anavex.com/wp-content/uploads/2018/07/Anavex-AAIC-2018-DT-01-Presentation.pdf

Hampel at the VI International Congress on Research and Innovation in Neurodegenerative Diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143924640

Comments on the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921147

Hampel's new web site on precision medicine features his presentation on 2-73.
https://www.apmiscience.com/interviews
_________________________________________________________________________________________________________________________
PRESS AND THIRD PARTY COVERAGE:

Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/

Another article by Ariana Pharma on their website, this time highlighting the CTAD presentation:
http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/

Thanks to polarbear for this link.. all I can say is "It's about time"...
https://alzheimersnewstoday.com/2018/10/31/anavex-2-73-slows-cognitive-decline-alzheimers-extension-study/

Press coverage of AVXL at 2018 CTAD:
http://cnafinance.com/anavex-life-sciences-avxl-stock-gaining-on-clinical-data/20696
http://www.bioworld.com/content/tiny-anavex-thinks-big-three-year-ad-data-ctad

New press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:
https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73

Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822
Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results

Videos of Australian Patients from the P2a trial

UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909

From K9uwa aka John: Today in Parkinsons News Today ENROLLING NOW in Spain article.
http://parkinsonsnewstoday.com/2018/11/01/anavex-recruiting-parkinsons-dementia-patients-spain-anavex-2-73-trial/

_________________________________________________________________________________________________________________________
AUDIO PRESENTATIONS:

Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference
October 3, 2018 2:50 p.m.

Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470
_________________________________________________________________________________________________________________________
VIDEO PRESENTATIONS

Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781

History of rettsyndrome.org featuring Christopher Missling:

Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208

_________________________________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:

From TTTav: October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf

Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims

CTAD 2018 slides - see the following grouping
_________________________________________________________________________________________________________________________
OCTOBER 2018 CTAD Presentations:

Poster available during the duration of CTAD:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1 , Michael Kornhauser BPharm1 , Ella Modini BSc1 , Harald Hampel, MD PhD2 , Stephan Toutain MS3, Christopher Missling PhD3

Friday, October 26 - Late Breaking Session
3.30 - 3.45 p.m. LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1 , Mohammad Afshar, MD, PhD2 , Frédéric Parmentier, PhD2 , Coralie Williams, MSc2 , Adrien Etcheto, MSc2 , Federico Goodsaid, PhD3 , Christopher U Missling, PhD4
****Information on Federico Goodsaid,Regulatory Pathfinders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatorypathfinders (Thanks blanka)

Saturday, October 27- Oral communications:
1.30 - 1.45 p.m. OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation Gustavo A. Jimenez-Maggiora, MBA1 , Rema Raman, PhD1 , Michael S. Rafii, MD, PhD1 , Reisa Anne Sperling, MD2,3, Jeffrey Lee Cummings, MD4, Paul S. Aisen, MD1

Slides from 2018 CTAD:
https://www.anavex.com/wp-content/uploads/2018/10/ANAVEX2-73_CTAD_2018_Presentation.pdf

Slide 16 shows good response in those with ApoE4 variant even though it is expected to be associated with faster rate of AD progression:
https://www.nature.com/articles/tpj200958
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144500445

Investor2014 on CTAD slides
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

CTAD overviews:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144493744
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

Some CTAD coverage:

_________________________________________________________________________________________________________________________
ALZHEIMER'S TRIAL DISCUSSIONS AND UPDATES:


https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role

Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423

Alzheimer's and Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134772774
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134771894

Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100

Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335

On dosage of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639

Discussion of P2a trial dropouts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144496759

See also CTAD 2018 discussions in group above.
_________________________________________________________________________________________________________________________
PARKINSON'S DEMENTIA TRIAL DISCUSSIONS AND UPDATES:

How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569

Biostockclub on Parkinsons dosage:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144533102

note: I know I've missed some good stuff here. Will search some more or let me know.
_________________________________________________________________________________________________________________________
RETT SYNDROME TRIAL DISCUSSIONS AND UPDATES:

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers
https://www.anavex.com/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex2-73-in-patients-with-rett-syndrome/

Will the trial be moved to Australia?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144362026

On Rett Syndrome and the M4 Receptor from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144347886
Discussion of Rett Trial Design:
https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=169067&BatchSize=20

Other Rett Syndrome related posts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144357506
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135703149

Talon38 provided this NIH link on Rett Syndrome:
https://ghr.nlm.nih.gov/condition/rett-syndrome

dadofmarcmax on Rett Syndrome and other epileptic diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135019599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135028269

Paper on Rett Syndrome treatment procedures:
https://pdfs.semanticscholar.org/c2c8/1063888a7aecffd3b1fe74a7b67496b2554f.pdf

The significance of Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640

PennyDouble reminds us:
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/

_________________________________________________________________________________________________________________________
ON U.S. PARTICIPATION IN TRIALS:

Timeline for ACTC participation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503

_________________________________________________________________________________________________________________________
GUT and BRAIN:

HOMEOSTATIC NETWORKING: THE ROLE OF PHYTOCHEMISTRY, THE ENDOCANNABINOID SYSTEM AND POTENTIAL FUTURE THERAPEUTICS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361

Restoration of gut microbiota as MOA in a possibly competitive Chinese compound:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144442713

XenaLives posts on gut/brain:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443836
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443854
_________________________________________________________________________________________________________________________
GENERAL DISCUSSIONS AND UPDATES:

An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176

Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285

Link to PeterKarol's blog:
https://piotrpeterblog.com/

Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988


CRISPER discover of likely MOA for 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274561

From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neurodegenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865

Missling has a strategy - ideas from two posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599

Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184

Anavex also has Orphan Drug Designation for Infantile Spasms:
https://www.anavex.com/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantile-spasms/

Dangerous medicines and mitochondrial dysfunction:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142393634&txt2find=mitochondrial

On Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144599308

What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471

Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889

Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772

AVXL 2-73 and cerebral blood flow:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143582952

Of Mice and Men - Alzheimer's drug development through the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143978495

Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently

Dr. Tanzi on infection and Alzheimer's, also "soda brain".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979877

Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467&txt2find=shareholder|meeting
_________________________________________________________________________________________________________________________
BIIB AND OTHER POTENTIAL PARTNER DISCUSSION:

Did BIIB blink?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143525102

Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135630393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837